Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

Clinical Validation and Distribution Expansion Drive Incremental Growth for ScleroSafe Platform

By The Northwire Desk — AI Analysis Apr 30, 2026 · 08:30 TSXV:
Executive Summary
  • VVT Med Inc. announced the publication of peer-reviewed clinical data in the Indian Journal of Vascular and Endovascular Surgery on April 30, 2026.
  • The study evaluated the ScleroSafe catheter-directed sclerotherapy system for symptomatic primary varicose veins.
  • Results showed a 100% clinical success rate in 30 patients with 95% vein occlusion at day 30 and 92% at day 90.
  • No serious complications such as deep vein thrombosis or skin necrosis were observed during the 90-day follow-up.
  • On April 27, 2026, VVT Med signed its largest European distribution agreement with Uber Ros S.p.A. for Italy, Vatican City, and San Marino.
  • The five-year agreement includes minimum purchase commitments valued at approximately CAD $2.3 million in potential revenue.
  • Uber Ros S.p.A. also participated as an investor in the Company's non-brokered private placement.
  • CapitaLynx Ltd was engaged for Investor Relations services at a cost of US$12,500 per month after an initial term.
Material Impact
  • The clinical data provides external validation but is based on a small observational cohort (30 patients), which limits statistical significance compared to randomized controlled trials typically required for major valuation inflection points.
  • While the 100% success rate is positive, it aligns with existing FDA-cleared and CE-marked status claims rather than introducing new regulatory milestones that would fundamentally alter risk profiles.
  • The distribution agreement adds revenue visibility but represents a modest annualized run-rate (~$460k/year) relative to typical small-cap medtech expectations unless the company is pre-revenue or early-stage.
  • Investor participation by Uber Ros signals confidence in the product's fit within their portfolio, yet the total size of the private placement remains undisclosed, leaving dilution risk ambiguous.
  • The engagement of an IR firm at a fixed monthly cost introduces a recurring cash burn expense that must be weighed against liquidity needs.
  • Overall, the news reinforces the commercialization thesis without materially de-risking the investment to the extent of warranting a "Game Changer" classification in a risk-averse framework.
TSXV: · Price
Company Overview
  • VVT Med Inc. develops the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) technology for treating venous disease.
  • The platform utilizes simultaneous sclerosant injection and blood aspiration to treat varicose veins.
  • The product holds FDA clearance and CE marking status prior to these news releases.
  • Flagship project is the commercialization of ScleroSafe in global markets, with recent focus on European expansion (Italy) and clinical validation in India.
Read the original news release →

More from

Jun 11, 2026 · 08:30

VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing

Financings May 26, 2026 · 08:00

VVT Med Executes European Rollout with First Italian Patient Treatments Following Strong Clinical Validation

Production / Operations Apr 27, 2026 · 09:00

VVT Med Secures Italian Distribution with Investor Participation, Incremental Revenue Stream Established

M&A / Property